SEARCH

SEARCH BY CITATION

References

  • Bae SK, Yang KH, Aryal DK, Kim YG, Lee MG. (2009) Pharmacokinetics of amitriptyline and one of its metabolites, nortriptyline, in rats: little contribution of considerable hepatic first-pass effect to low bioavailability of amitriptyline due to great intestinal first-pass effect. J Pharmaceut Sci 98:15871601.
  • Barton ME, Klein BD, Wolf HH, White HS. (2001) Pharmacological characterization of the 6 Hz psychomotor seizure model of partial epilepsy. Epilepsy Res 47:217227.
  • Battino D, Tomson T. (2007) Management of epilepsy during pregnancy. Drugs 67:27272746.
  • Bialer M, Hadad S, Kadry B, Abdul-Hai A, Haj Yehia A, Sterling J, Herzig Y, Yagen B. (1996) Pharmacokinetic analysis and antiepileptic activity of tetramethylcyclopropyl analogues of valpromide. Pharm Res 13:284289.
  • Bialer M, Yagen B. (2007) Valproic acid: second generation. Neurotherapeutics 4:130137.
  • Bialer M, White HS. (2010) Key factors in the discovery and development of new antiepileptic drugs. Nat Rev Drug Discov 9:6882.
  • Chang TKH, Abbott FS. (2006) Oxidative stress as mechanism of valproic acid hepatotoxicity. Drug Metab Disposit 28:627639.
  • Dubuisson D, Dennis SG. (1977) The formalin test: a quantitative study of the analgesic effects of morphine, meperidine, and brain stem stimulation in rats and cats. Pain 4:161174.
  • Finnell RH, Bennett GD, Karras SB, Mohl VK. (1988) Common hierarchies of susceptibility to the induction of neural tube defects in mouse embryos by valproic acid and its 4-propyl-4-pentenoic acid metabolite. Teratology 38:313320.
  • Finnell RH, Bielec B, Nau H. (1997). Anticonvulsant drugs: mechanisms and pathogenesis of teratogenicity. Handb Exp Pharmacol 124 (Drug Toxicity in Embryonic Development II): 121159.
  • Guindon J, Walczak JS, Beaulieu P. (2007) Recent advances in the pharmacological management of pain. Drugs 67:21212133.
  • Isoherranen N, White HS, Finnell RH, Yagen B, Woodhead JH, Bennett GD, Wilcox KS, Barton ME, Bialer M. (2002) Anticonvulsant profile and teratogenicity of N-methyl-tetramethylcyclopropyl carboxamide: a new antiepileptic drug. Epilepsia 43:115126.
  • Isoherranen N, Levy RH, Yagen B, Woodhead JH, White HS, Bialer M. (2004) Metabolism of a new antiepileptic drug, N-methyl-tetramethylcyclopropanecarboxamide, and anticonvulsant activity of its metabolites. Epilepsy Res 58:112.
  • Kaneko H, Shiba K, Yoshitake A, Miyamoto J. (1987) Metabolism of fenpropathrin in rats. Nippon Noyaku Gakkaishi 12:385395.
  • Kaneko S, Battino D, Andermann E, Wada K, Kan R, Takeda A, Nakane Y, Ogawa Y, Avanzini G, Fumarola C, Granata T, Molteni F, Pardi G, Minotti L, Canger R, Dansky L, Oguni M, Lopes-Cendas I, Sherwin A, Andermann F, Seni MH, Okada M, Teranishi T. (1999) Congenital malformations due to antiepileptic drugs. Epilepsy Res 33:145158.
  • Kaufmann D, Bialer M, Shimshoni JA, Devor M, Yagen B. (2009) Synthesis and evaluation of antiallodynic activity of novel amide and urea derivatives of valproic acid analogues. J Med Chem 52:72367248.
  • Kim SH, Chung JM. (1992) An experimental model for peripheral neuropathy produced by segmental spinal nerve ligation in the rat. Pain 50:355363.
  • Koenig SA, Buesing D, Longin E, Oehring R, Haussermann P, Kluger G, Lindmayer F, Hanusch R, Degen I, Kuhn H, Samii K, Jungck A, Bruckner R, Seitz R, Boxtermann W, Weber Y, Knapp R, Richard HH, Weidner B, Kasper JM, Haensch CA, Fitzek S, Hartmann M, Borusiak P, Muller-Deile A, Degenhardt V, Korenke GC, Hoppen T, Specht U, Gerstner T. (2006) Valproic acid-induced hepatopathy: nine new fatalities in Germany from 1994 to 2003. Epilepsia 47:20272031.
  • Meador KJ. (2008) Effect of in-utero antiepileptic drug exposure. Epilepsy Curr 8:144147.
  • Mihara K, Ohkawa H, Miyamoto J, Miyamoto J. (1981) Metabolism of terallethrin in rats. Nippon Noyaku Gakkaishi 6:211222.
  • Morrell MJ. (1996) The new antiepileptic drugs and women: efficacy, reproductive health, pregnancy, and fetal outcome. Epilepsia 37(suppl 6):S34S44.
  • Nalivaeva NN, Belyaev ND, Turner AJ. (2009) Sodium valproate: an old drug with new roles. Trends Pharmacol Sci 30:509514.
  • Neuman MG, Shear NH, Jacobson-Brown PM, Katz GG, Neilson HK, Malkiewicz IM, Cameron RG, Abbott F. (2001) CYP2E1-mediated modulation of valproic acid-induced hepatocytotoxicity. Clin Biochem 34:211218.
  • Palmieri C, Canger R. (2002) Teratogenic potential of the newer antiepileptic drugs. CNS Drugs 16:755764.
  • Perucca E. (2002) Pharmacological and therapeutic properties of valproic acid: a summary after 35 years of clinical experience. CNS Drugs 16:695714.
  • Pessah N, Bialer M, Wlodarczyk B, Finnell RH, Yagen B. (2009) α-Fluoro-2,2,3,3-tetramethylcyclopropanecarboxamide, a novel potent anticonvulsant derivative of a cyclic analogue of valproic acid. J Med Chem 52:22332242.
  • Racine RJ. (1972) Modification of seizure activity by electrical stimulation, II: motor seizure. Electroencephalogr Clin Neurophysiol 32:281294.
  • Rowland M, Tozer T. (2009) Clinical pharmacokinetics and pharmacodynamics, 4th ed. Wolters Kluwers/Lippincott Williams & Wilkins, Philadelphia, PA, U.S.A.
  • Shannon HE, Lutz Eberele E, Peters SC. (2005) Comparison of the effect of anticonvulsant drugs with diverse mechanisms of action in the formalin test in rats. Neuropharmacology 48:10121020.
  • Shimshoni J, Bialer M, Yagen B. (2008) Synthesis and anticonvulsant activity of new tetramethylcyclpopropylcarboaxamide aromatic derivatives. Bioorg Med Chem 16:62976305.
  • Sobol E, Bialer M, Yagen B. (2004) Tetramethylcyclopropyl analogue of a leading antiepileptic drug-valproic acid. Synthesis and evaluation of the anticonvulsant activity of its amide derivatives. J Med Chem 47:43164326.
  • Sobol E, Yagen B, Winkler I, Britzi M, Gibson D, Bialer M. (2005) Pharmacokinetics and metabolism of a new potent anticonvulsant agent, 2,2,3,3-tertarmethylyclopropylcarbonylurea. Drug Metab Dispos 33:15381546.
  • Tang W, Borel AG, Fujimiya T, Abbott FS. (1995) Fluorinated analogs as mechanistic probes in valproic acid hepatotoxicity: hepatic microvesicular steatosis and glutathione status. Chem Res Toxicol 8:671682.
  • Wheeler-Aceto H, Porreca F, Cowan A. (1990) The rat paw formalin test: comparison of noxious agents. Pain 40:229238.
  • White HS, Woodhead JH, Wilcox KS, Stables JP, Kupferberg HJ, Wolf HH. (2002) Discovery and preclinical development of antiepileptic drugs. In LevyRH, MattsonRH, MeldrumBS, PeruccaE (Eds) Antiepileptic Drugs, 5th ed. E. Lippincott Williams & Wilkins Publishers, New York, pp. 3648.
  • Winkler I, Sobol E, Yagen B, Steinman A, Devor M, Bialer M. (2005) Efficacy of antiepileptic tetramethylcyclopropyl analogues of valproic acid amides in a rat model of neuropathic pain. Neuropharmacology 49:11101120.
  • Yang SH, Lee MG. (2008) Dose-independent pharmacokinetics of ondansetron in rats: contribution of hepatic and intestinal first pass effects to low bioavailability. Biopharm Drug Dispos 29:414426.